In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics (DRMA – Research Report). The company’s shares closed yesterday at $0.39.
According to TipRanks, Vendetti is an analyst with an average return of -4.3% and a 32.40% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Biolase, Sensus Healthcare, and Electrocore.
The analyst consensus on Dermata Therapeutics is currently a Moderate Buy rating.
Based on Dermata Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.72 million. In comparison, last year the company had a GAAP net loss of $2.42 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermata Therapeutics (DRMA) Company Description:
Dermata Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.
Read More on DRMA:
